Page 147 - 2019_08-Haematologica-web

A novel anti-CD19 antibody drug conjugate
Alkylating Activity, Exhibits Potent Antitumor Activity in Models of AML. Mol Cancer Ther. 2018;17(6):1271-1279.
25. Cortes JE, Traer E, Wang ES, et al. IMGN779, a Next-Generation CD33- Targeting Antibody-Drug Conjugate (ADC) Demonstrates Initial Antileukemia Activity in Patients with Relapsed or Refractory Acute Myeloid Leukemia. Blood. 2017;130(Suppl 1):1312-1312.
26. Tarantelli C, Gaudio E, Arribas AJ, et al. PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy. Clin Cancer Res. 2018;24(1):120-129.
27. Hicks SW, Lai KC, Gavrilescu LC, et al. The Antitumor Activity of IMGN529, a CD37- Targeting Antibody-Drug Conjugate, Is Potentiated by Rituximab in Non-Hodgkin Lymphoma Models. Neoplasia. 2017;19(9):661-671.
28. Al-Katib AM, Aboukameel A, Mohammad R, Bissery MC, Zuany-Amorim C. Superior antitumor activity of SAR3419 to rituximab in xenograft models for non-Hodgkin's lymphoma. Clin Cancer Res. 2009;15(12):4038-4045.
29. Kantarjian HM, Lioure B, Kim SK, et al. A Phase II Study of Coltuximab Ravtansine (SAR3419) Monotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk. 2016;16(3):139-145.
30. Yu SF, Zheng B, Go M, et al. A Novel Anti- CD22 Anthracycline-Based Antibody-Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs. Clin Cancer Res. 2015;21(14):3298-3306.
31. Deckert J, Park PU, Chicklas S, et al. A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies. Blood. 2013;122(20):3500-3510.
32. Przepiorka D, Ko CW, Deisseroth A, et al. FDA Approval: Blinatumomab. Clin Cancer Res. 2015;21(18):4035-4039.
33. Pulte ED, Vallejo J, Przepiorka D, et al. FDA Supplemental Approval: Blinatumomab for Treatment of Relapsed and Refractory Precursor B-Cell Acute Lymphoblastic Leukemia. Oncologist. 2018;23(11):1366- 1371.
34. Jen EY, Xu Q, Schetter A, et al. FDA Approval: Blinatumomab for Patients with B-cell Precursor Acute Lymphoblastic
Leukemia in Morphologic Remission with Minimal Residual Disease. Clin Cancer Res. 2019;25(2):173-477.
35. O'Leary MC, Lu X, Huang Y, et al. FDA Approval summary: tisagenlecleucel for treatment of patients with relapsed or refractory B-cell precursor acute lym- phoblastic leukemia. Clin Cancer Res. 2018 Oct 11. [Epub ahead of print]
36. Bouchkouj N, Kasamon YL, de Claro RA, et al. FDA Approval summary: axicabtagene ciloleucel for relapsed or refractory large B- cell lymphoma. Clin Cancer Res. 2018 Nov 9. [Epub ahead of print]
37. Chow VA, Shadman M, Gopal AK. Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma. Blood. 2018;132(8):777-781.
38. Jurczak W, Zinzani PL, Gaidano G, et al. Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin's lym- phoma. Ann Oncol. 2018;29(5):1266-1272.
39. Munshi PN, Ujjani C. The acceleration of CAR-T therapy in non-Hodgkin lym- phoma. Hematol Oncol. 2018 Nov 14. [Epub ahead of print]
haematologica | 2019; 104(8)
1639